GH
Guardant Health, Inc. NASDAQ Listed Oct 4, 2018$131.78
+2.07%
vs $129.11
Mkt Cap $17.5B
52w Low $40.35
96.6% of range
52w High $135.00
50d MA $105.79
200d MA $93.91
P/E (TTM)
-39.7x
EV/EBITDA
—
P/B
—
Debt/Equity
-16.9x
ROE
419.2%
P/FCF
-70.9x
RSI (14)
53.00
ATR (14)
$6.05
Beta
1.65
50d MA
$105.79
200d MA
$93.91
Avg Volume
2.4M
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing LUNAR-2 test for the early detection of colorectal cancer in asymptomatic individuals eligible; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials. In addition, the company offers Guardant Reveal Test for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; Guardant360 tissue genotyping product; and Guardant-19 for use in the detection of the novel coronavirus. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, and kits fulfillment related services to biopharmaceutical companies and medical institutions. The company was incorporated in 2011 and is headquartered in Redwood City, California.
505 Penobscot Drive · Palo Alto, CA 94063 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 7, 2026 | AMC | -0.47 | -0.85 | -80.9% | 92.26 | +4.7% | +3.7% | +1.1% | +3.3% | -1.5% | +0.2% | — |
| Feb 19, 2026 | AMC | -0.77 | -0.90 | -17.4% | 106.38 | +1.5% | -3.1% | -8.4% | +1.0% | -0.1% | +2.8% | — |
| Oct 29, 2025 | AMC | -0.48 | -0.39 | +18.8% | 72.27 | +24.5% | +27.9% | +0.7% | +6.3% | -0.8% | -3.1% | — |
| Jul 30, 2025 | AMC | -0.52 | -0.44 | +15.4% | 45.19 | -0.7% | -9.3% | +1.1% | +6.7% | +4.5% | -3.4% | — |
| Apr 30, 2025 | AMC | -0.61 | -0.49 | +19.7% | 47.23 | +11.5% | +3.5% | -4.1% | -6.0% | -4.8% | -5.2% | — |
| Feb 20, 2025 | AMC | -0.75 | -0.62 | +17.3% | 47.40 | +2.3% | -9.6% | -1.0% | -4.9% | +7.0% | -2.5% | — |
| Nov 6, 2024 | AMC | -0.55 | -0.45 | +18.2% | 25.29 | +28.1% | +13.0% | +0.1% | +2.6% | +1.3% | +6.3% | — |
| Aug 7, 2024 | AMC | -0.57 | -0.48 | +15.8% | 33.96 | -5.6% | -10.9% | -4.2% | +5.1% | -2.4% | -2.3% | — |
| May 9, 2024 | AMC | -0.72 | -0.46 | +36.1% | 19.44 | +10.2% | +15.1% | +7.3% | +3.0% | +4.1% | +1.9% | — |
| Feb 22, 2024 | AMC | -0.93 | -1.58 | -69.9% | 22.27 | -5.7% | -12.8% | +3.7% | -3.0% | -4.1% | +1.4% | — |
| Nov 6, 2023 | AMC | -0.93 | -0.73 | +21.5% | 27.74 | -2.3% | -5.4% | -9.8% | -5.0% | -4.0% | +4.9% | — |
| Aug 3, 2023 | AMC | -1.25 | -0.67 | +46.4% | 35.54 | +2.9% | +6.4% | -0.8% | -1.8% | -1.0% | -1.0% | — |
| May 9, 2023 | AMC | -1.26 | -1.30 | -3.2% | 23.99 | +8.3% | +14.9% | -1.7% | -2.7% | +5.8% | -2.3% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 12 | RBC Capital Mkts | Initiates | Outperform | $185 | $130.90 | $133.15 | +1.7% | +0.6% | -1.4% | -1.9% | +1.4% | +2.1% |
| Jun 5 | Goldman | Initiates | Buy | $165 | $133.06 | $133.00 | -0.0% | -5.6% | -0.6% | +4.2% | +0.4% | +0.2% |
| Jun 2 | Evercore ISI | Upgrade | In-line → Outperform | $160 | $129.14 | $131.88 | +2.1% | +0.8% | -2.4% | +4.7% | -5.6% | -0.6% |
| Jun 2 | Wolfe Research | Reiterates | Outperform | $150 | $129.14 | $131.88 | +2.1% | +0.8% | -2.4% | +4.7% | -5.6% | -0.6% |
| Apr 14 | Barclays | Maintains | Overweight → Overweight | — | $82.21 | $83.04 | +1.0% | +5.1% | -1.8% | +1.0% | +5.4% | +0.8% |
| Apr 6 | Evercore ISI | Maintains | In Line → In Line | — | $93.83 | $92.68 | -1.2% | -4.4% | +4.1% | -0.5% | -6.1% | -9.8% |
| Feb 24 | Piper Sandler | Maintains | Overweight → Overweight | — | $94.42 | $95.42 | +1.1% | +1.0% | -0.1% | +2.8% | -4.2% | -1.8% |
| Feb 20 | TD Cowen | Maintains | Buy → Buy | — | $106.38 | $108.00 | +1.5% | -3.1% | -8.4% | +1.0% | -0.1% | +2.8% |
| Feb 20 | BTIG | Maintains | Buy → Buy | — | $106.38 | $108.00 | +1.5% | -3.1% | -8.4% | +1.0% | -0.1% | +2.8% |
| Feb 20 | Evercore ISI | Maintains | In Line → In Line | — | $106.38 | $108.00 | +1.5% | -3.1% | -8.4% | +1.0% | -0.1% | +2.8% |
| Feb 20 | Leerink Partners | Maintains | Outperform → Outperform | — | $106.38 | $108.00 | +1.5% | -3.1% | -8.4% | +1.0% | -0.1% | +2.8% |
| Feb 20 | Citigroup | Maintains | Buy → Buy | — | $106.38 | $108.00 | +1.5% | -3.1% | -8.4% | +1.0% | -0.1% | +2.8% |
| Feb 20 | Canaccord Genuity | Maintains | Buy → Buy | — | $106.38 | $108.00 | +1.5% | -3.1% | -8.4% | +1.0% | -0.1% | +2.8% |
| Feb 20 | Wells Fargo | Maintains | Overweight → Overweight | — | $106.38 | $108.00 | +1.5% | -3.1% | -8.4% | +1.0% | -0.1% | +2.8% |
| Feb 20 | JP Morgan | Maintains | Overweight → Overweight | — | $106.38 | $108.00 | +1.5% | -3.1% | -8.4% | +1.0% | -0.1% | +2.8% |
| Feb 20 | Stifel | Maintains | Buy → Buy | — | $106.38 | $108.00 | +1.5% | -3.1% | -8.4% | +1.0% | -0.1% | +2.8% |
| Jan 26 | Guggenheim | Maintains | Buy → Buy | — | $114.75 | $114.15 | -0.5% | -0.0% | -0.1% | -4.2% | +0.7% | +3.2% |
| Jan 9 | Stifel | Maintains | Buy → Buy | — | $108.74 | $108.17 | -0.5% | +1.3% | -2.4% | -0.6% | +1.6% | +3.1% |
| Jan 5 | Guggenheim | Maintains | Buy → Buy | — | $101.74 | $101.10 | -0.6% | +0.1% | +10.3% | -2.1% | -1.1% | +1.3% |
| Jan 5 | Evercore ISI | Downgrade | Outperform → In Line | — | $101.74 | $101.10 | -0.6% | +0.1% | +10.3% | -2.1% | -1.1% | +1.3% |
| Dec 22 | Canaccord Genuity | Maintains | Buy → Buy | — | $99.74 | $100.93 | +1.2% | +1.6% | +1.1% | -0.1% | +0.6% | -1.5% |
| Dec 17 | Mizuho | Maintains | Outperform → Outperform | — | $100.00 | $101.46 | +1.5% | -2.5% | -0.4% | +2.7% | +1.6% | +1.1% |
| Dec 15 | Barclays | Maintains | Overweight → Overweight | — | $102.07 | $104.12 | +2.0% | +0.6% | -2.6% | -2.5% | -0.4% | +2.7% |
| Dec 15 | Leerink Partners | Maintains | Outperform → Outperform | — | $102.07 | $104.12 | +2.0% | +0.6% | -2.6% | -2.5% | -0.4% | +2.7% |
| Dec 15 | JP Morgan | Maintains | Overweight → Overweight | — | $102.07 | $104.12 | +2.0% | +0.6% | -2.6% | -2.5% | -0.4% | +2.7% |
| Dec 15 | Wells Fargo | Maintains | Overweight → Overweight | — | $102.07 | $104.12 | +2.0% | +0.6% | -2.6% | -2.5% | -0.4% | +2.7% |
| Dec 12 | BTIG | Maintains | Buy → Buy | — | $101.38 | $103.52 | +2.1% | +0.7% | +0.6% | -2.6% | -2.5% | -0.4% |
| Dec 11 | Citigroup | Maintains | Buy → Buy | — | $102.62 | $104.36 | +1.7% | -1.2% | +0.7% | +0.6% | -2.6% | -2.5% |
| Dec 2 | Morgan Stanley | Maintains | Overweight → Overweight | — | $105.22 | $106.62 | +1.3% | -1.3% | +2.0% | +2.4% | -6.0% | +2.1% |
| Oct 30 | UBS | Maintains | Buy → Buy | — | $72.27 | $89.99 | +24.5% | +27.9% | +0.7% | +6.3% | -0.8% | -3.1% |
| Oct 30 | BTIG | Maintains | Buy → Buy | — | $72.27 | $89.99 | +24.5% | +27.9% | +0.7% | +6.3% | -0.8% | -3.1% |
| Oct 30 | Canaccord Genuity | Maintains | Buy → Buy | — | $72.27 | $89.99 | +24.5% | +27.9% | +0.7% | +6.3% | -0.8% | -3.1% |
| Oct 30 | Evercore ISI | Maintains | Outperform → Outperform | — | $72.27 | $89.99 | +24.5% | +27.9% | +0.7% | +6.3% | -0.8% | -3.1% |
| Oct 30 | Barclays | Maintains | Overweight → Overweight | — | $72.27 | $89.99 | +24.5% | +27.9% | +0.7% | +6.3% | -0.8% | -3.1% |
| Oct 30 | Citigroup | Maintains | Buy → Buy | — | $72.27 | $89.99 | +24.5% | +27.9% | +0.7% | +6.3% | -0.8% | -3.1% |
| Oct 22 | Piper Sandler | Maintains | Overweight → Overweight | — | $67.51 | $69.23 | +2.5% | +0.8% | +1.9% | +4.0% | -1.8% | -1.8% |
| Oct 7 | Evercore ISI | Maintains | Outperform → Outperform | — | $63.38 | $63.27 | -0.2% | +0.1% | +3.0% | -0.1% | -1.6% | -3.9% |
| Oct 2 | Barclays | Maintains | Overweight → Overweight | — | $62.65 | $62.60 | -0.1% | -1.9% | +2.2% | +0.9% | +0.1% | +3.0% |
| Sep 26 | Canaccord Genuity | Maintains | Buy → Buy | — | $60.18 | $60.18 | +0.0% | -0.2% | +3.3% | +0.8% | +0.3% | -1.9% |
| Sep 25 | Leerink Partners | Maintains | Outperform → Outperform | — | $57.67 | $59.37 | +2.9% | +4.4% | -0.2% | +3.3% | +0.8% | +0.3% |
| Sep 25 | Guggenheim | Maintains | Buy → Buy | — | $57.67 | $59.37 | +2.9% | +4.4% | -0.2% | +3.3% | +0.8% | +0.3% |
| Sep 25 | JP Morgan | Maintains | Overweight → Overweight | — | $57.67 | $59.37 | +2.9% | +4.4% | -0.2% | +3.3% | +0.8% | +0.3% |
| Sep 25 | TD Cowen | Maintains | Buy → Buy | — | $57.67 | $59.37 | +2.9% | +4.4% | -0.2% | +3.3% | +0.8% | +0.3% |
| Sep 25 | Stifel | Maintains | Buy → Buy | — | $57.67 | $59.37 | +2.9% | +4.4% | -0.2% | +3.3% | +0.8% | +0.3% |
| Sep 25 | BTIG | Maintains | Buy → Buy | — | $57.67 | $59.37 | +2.9% | +4.4% | -0.2% | +3.3% | +0.8% | +0.3% |
| Sep 25 | Mizuho | Maintains | Outperform → Outperform | — | $57.67 | $59.37 | +2.9% | +4.4% | -0.2% | +3.3% | +0.8% | +0.3% |
| Sep 25 | Wolfe Research | Upgrade | Peer Perform → Outperform | — | $57.67 | $59.37 | +2.9% | +4.4% | -0.2% | +3.3% | +0.8% | +0.3% |
| Sep 25 | UBS | Maintains | Buy → Buy | — | $57.67 | $59.37 | +2.9% | +4.4% | -0.2% | +3.3% | +0.8% | +0.3% |
| Sep 22 | BTIG | Maintains | Buy → Buy | — | $59.15 | $59.80 | +1.1% | +1.1% | -0.1% | -3.4% | +4.4% | -0.2% |
| Sep 4 | BTIG | Maintains | Buy → Buy | — | $65.06 | $60.00 | -7.8% | -5.7% | -2.0% | +0.1% | -1.2% | -4.8% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Jun 16, 2026 | Tariq MusaDir | — | Sell | 116 | $130.19 | $15K | 8,796 | +1.39% | — |
| Jun 11, 2026 | Kalia KumudOff | Chief Information Officer | Sell | 3,418 | $130.24 | $445K | 41,090 | -1.91% | — |
| Jun 10, 2026 | Kalia KumudOff | Chief Information Officer | Sell | 5,000 | $130.41 | $652K | 44,508 | -1.37% | — |
| Jun 5, 2026 | Bell Michael BrianOff | Chief Financial Officer | Sell | 2,000 | $128.62 | $257K | 47,509 | +4.19% | -1.37% |
| Jun 5, 2026 | Eltoukhy HelmyDir/Off | Co-Chief Executive Officer | Sell | 100 | $132.55 | $13K | 2,012,919 | +4.19% | -1.37% |
| Jun 5, 2026 | Eltoukhy HelmyDir/Off | Co-Chief Executive Officer | Sell | 900 | $131.78 | $119K | 2,013,019 | +4.19% | -1.37% |
| Jun 5, 2026 | Eltoukhy HelmyDir/Off | Co-Chief Executive Officer | Sell | 554 | $130.21 | $72K | 2,013,919 | +4.19% | -1.37% |
| Jun 5, 2026 | Eltoukhy HelmyDir/Off | Co-Chief Executive Officer | Sell | 13,787 | $128.25 | $1.8M | 2,014,473 | +4.19% | -1.37% |
| Jun 5, 2026 | Eltoukhy HelmyDir/Off | Co-Chief Executive Officer | Sell | 1,100 | $127.02 | $140K | 2,028,260 | +4.19% | -1.37% |
| Jun 5, 2026 | Eltoukhy HelmyDir/Off | Co-Chief Executive Officer | Sell | 33,843 | $126.33 | $4.3M | 2,029,360 | +4.19% | -1.37% |
| Jun 5, 2026 | Eltoukhy HelmyDir/Off | Co-Chief Executive Officer | Sell | 49,716 | $125.57 | $6.2M | 2,063,203 | +4.19% | -1.37% |
| Jun 3, 2026 | Joyce Meghan V.Dir | — | Sell | 106 | $129.31 | $14K | 11,183 | -5.60% | +0.15% |
| Jun 3, 2026 | Joyce Meghan V.Dir | — | Sell | 650 | $128.02 | $83K | 11,289 | -5.60% | +0.15% |
| Jun 3, 2026 | Joyce Meghan V.Dir | — | Sell | 5,728 | $127.11 | $728K | 11,939 | -5.60% | +0.15% |
| Jun 3, 2026 | Joyce Meghan V.Dir | — | Sell | 3,516 | $126.52 | $445K | 17,667 | -5.60% | +0.15% |
| May 27, 2026 | Saia John G.Off | Chief Legal Officer | Sell | 6 | $126.08 | $756 | 35,950 | -2.65% | +4.75% |
| May 27, 2026 | Saia John G.Off | Chief Legal Officer | Sell | 9,994 | $125.08 | $1.3M | 35,956 | -2.65% | +4.75% |
| May 22, 2026 | Freeman ChrisOff | Chief Commercial Officer | Sell | 24,406 | $118.67 | $2.9M | 60,034 | +6.39% | +0.80% |
| May 18, 2026 | Tariq MusaDir | — | Sell | 116 | $95.96 | $11K | 8,662 | +17.09% | +6.39% |
| May 12, 2026 | Talasaz AmirAliDir/Off | Co-Chief Executive Officer | Sell | 50,000 | $100.32 | $5.0M | 2,096,504 | +0.19% | +17.09% |
8-K
Guardant Health, Inc. -- 8-K Filing
Guardant Health filed an 8-K with the SEC, likely containing material events or updates affecting the oncology diagnostics company that investors should monitor for potential impacts on stock performance.
Apr 27
8-K
Guardant Health, Inc. -- 8-K Filing
Guardant Health delivered 39% revenue growth in Q4 2025 across oncology and screening, guiding 2026 revenue growth of 27-30%, signaling sustained expansion but moderating growth rate.
Feb 19
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Vanguard Portfolio Management Llc | 5,837,992 | $539M | New | Mar 2026 |
| 2 | Vanguard Capital Management Llc | 5,624,180 | $520M | New | Mar 2026 |
| 3 | Invesco Ltd. | 4,946,469 | $457M | Reduced | Mar 2026 |
| 4 | Two Sigma Investments, Lp | 4,229,531 | $391M | Added | Mar 2026 |
| 5 | Fmr Llc | 4,116,081 | $380M | Added | Mar 2026 |
| 6 | Franklin Resources Inc | 3,448,193 | $319M | Added | Mar 2026 |
| 7 | Morgan Stanley | 2,308,598 | $236M | Added | Dec 2025 |
| 8 | Lord, Abbett & Co. Llc | 1,899,113 | $175M | Reduced | Mar 2026 |
| 9 | Alyeska Investment Group, L.p. | 1,489,566 | $138M | Added | Mar 2026 |
| 10 | Rtw Investments, Lp | 1,481,033 | $137M | — | Mar 2026 |
| 11 | Ubs Group Ag | 1,405,837 | $130M | Reduced | Mar 2026 |
| 12 | Bank Of New York Mellon Corp | 1,391,187 | $129M | Added | Mar 2026 |
| 13 | Hood River Capital Management Llc | 1,310,065 | $121M | Added | Mar 2026 |
| 14 | Jennison Associates Llc | 1,170,337 | $120M | Reduced | Dec 2025 |
| 15 | Northern Trust Corp | 1,112,439 | $103M | Added | Mar 2026 |
| 16 | Temasek Holdings (Private) Ltd | 985,571 | $91M | Reduced | Mar 2026 |
| 17 | William Blair Investment Management, Llc | 951,114 | $88M | New | Mar 2026 |
| 18 | Millennium Management | 921,395 | $85M | Added | Mar 2026 |
| 19 | Bank Of America Corp /de/ | 895,221 | $83M | Added | Mar 2026 |
| 20 | Artisan Partners Limited Partnership | 814,571 | $75M | Added | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$17.47B
Enterprise Value
$17.00B
P/E (TTM)
-39.69x
Forward P/E
—
PEG Ratio
4.56x
P/B
—
P/S
16.82x
P/FCF
-70.89x
EV/EBITDA
—
Shares Out
125.4M
Financials (TTM)
Revenue
$982.0M
Net Income
-$416.3M
EBITDA
-$373.9M
Free Cash Flow
-$233.1M
Op Cash Flow
-$184.8M
EPS Basic
$-3.32
EPS Diluted
$-3.32
EPS Forward
$-2.96
Gross Margin
64.5%
Op Margin
-44.4%
Net Margin
-42.4%
Balance Sheet
Total Assets
$2.01B
Total Liab.
$2.11B
Total Equity
-$99.3M
Cash
$1.20B
LT Debt
$1.68B
Book Value/Sh
$-0.79
Debt/Equity
-16.94x
Current Ratio
4.84
Quick Ratio
4.56
Returns & Growth
ROE
419.2%
ROA
-20.7%
ROIC
-25.4%
Rev Growth YoY
+32.9%
EPS Growth YoY
+6.7%
Price Returns
2W
+31.5%
1M
+48.9%
3M
+38.1%
6M
+19.6%
12M
+219.3%
Technicals
52W High
$135.00
52W Low
$40.35
50d MA
$105.79
200d MA
$93.91
RSI (14)
53.00
ATR (14)
$6.05
Beta
1.65
Avg Volume
2.4M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$133.14
High
$175.00
Low
$110.00
Median
$130.00
Data updated apr 25, 2026 11:20am
· Source: financialmodelingprep.com